Health Evaluation in African Americans Using RAS Therapy (HEART)
Alzheimer's Disease
About this trial
This is an interventional prevention trial for Alzheimer's Disease focused on measuring hypertension, prevention, family history, inflammation, blood brain barrier, amyloid
Eligibility Criteria
Inclusion Criteria:
- Mean resting systolic blood pressure ≥ 110 mmHg and ≤ 170 mmHg
- Family history of Alzheimer's disease
- African American
Exclusion Criteria:
- Currently in another investigational drug study
- Potassium >5.0 meq/dL at baseline
- Creatinine >1.99 mg/dL at baseline
- History of stroke or transient ischemic attack (TIA)
- Dementia
- Current use of a RAS acting medication
- Contraindication for lumbar puncture or magnetic resonance imaging
- Heart failure
- Diabetes Types I and II
- Pregnant or nursing women
Sites / Locations
- Emory University
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Telmisartan 20mg
Telmisartan 40mg
Placebo
African American participants with and without hypertension and at high risk for Alzheimer's disease randomly assigned to receive telmisartan 20mg once a day orally.
African American participants with and without hypertension and at high risk for Alzheimer's disease randomly assigned to receive telmisartan 40mg once a day orally.
African American participants with and without hypertension and at high risk for Alzheimer's disease randomly assigned to receive a placebo to match telmisartan once a day orally.